MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ard.2025.03.007

Медицинская библиотека · Annals of the rheumatic diseases · 2025

Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis.

Kartawinata Melissa, Lin Wei-Yu, Jebson Beth, O'Brien Kathryn, Ralph Elizabeth, Welsh Emma, Restuadi Restuadi, Rosser Elizabeth C, Deakin Claire T, Wedderburn Lucy R, Wallace Chris, CLUSTER Consortium

СтатьяВалидационное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

To identify and validate gene expression biomarkers of response to methotrexate (MTX) treatment in peripheral blood of children with juvenile idiopathic arthritis (JIA) measured before starting MTX treatment.

METHODS

RNA sequencing was performed on sorted CD4+, CD8+, CD14+, and CD19+ cells, as well as peripheral blood mononuclear cells (PBMC) taken pre-treatment in a discovery cohort (n = 97) and 2 validation cohorts (n = 26 and n = 47, respectively) of patients with non-systemic JIA. Clinical data were recorded at baseline (timepoint 1) prior to treatment and 6 months (timepoint 2) of MTX treatment. Analysis tested the association of gene expression in specific cell types with treatment response using limma-voom, gene set enrichment analysis, and a novel 51-gene score against response to treatment. Parallel analysis, also using pre-treatment gene expression data, was performed in adult rheumatoid arthritis (RA) data (n = 240).

RESULTS

In patients with JIA, the baseline expression of genes driven by interferon (IFN) alpha (type-I) or gamma (type-II) was associated with response to treatment at 6 months in 3 independent JIA cohorts. The direction of the association indicated that children with higher baseline expression of IFN-stimulated genes prior to MTX were more likely to be good responders. Comparison with adult RA indicated differences between PBMC and whole blood gene expression associations with response.

CONCLUSIONS

In children with JIA, a high IFN-driven gene signature is associated with a better response to MTX than those with a low IFN-driven gene signature. These data could pave the way to clinically validated tools to identify those most likely to require medications in addition to MTX to control inflammation.

Для цитирования: Kartawinata Melissa, Lin Wei-Yu, Jebson Beth, O'Brien Kathryn, Ralph Elizabeth, Welsh Emma, Restuadi Restuadi, Rosser Elizabeth C, Deakin Claire T, Wedderburn Lucy R, Wallace Chris, CLUSTER Consortium. Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis.. Annals of the rheumatic diseases. 2025. DOI: 10.1016/j.ard.2025.03.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.